Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 33

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 33
---
 evaluate timing and structure of any deployment under this strategy.                                                                    
 Nasdaq Compliance and Reverse Split. Following a previously disclosed bid-price deficiency process, we effected a 1-for-10 reverse stock split on April 7, 2025, and on April 30, 2025, we received confirmation of regained compliance with Nasdaq Listing Rule 5550(a)(2).                                                                                                                                                                                                                                                      |
|:--|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| · | CFO Appointment. On June 17, 2025, we appointed Ms. Chong Set Fui (Angeline) as Chief Financial Officer and Principal Financial Officer.                                                                                                                                                                                                                                                                                                                                                                                          |
| · | Fidelion Term Sheet. On July 30, 2025, we entered into a non-binding term sheet with Fidelion Diagnostics Pte Ltd for a contemplated strategic, cross-equity alliance and exclusive commercialization rights for the VitaGuard™ minimal residual disease (MRD) platform in Southeast Asia, subject to execution of definitive agreements.                                                                                                                                                                                         |
| · | BirchBioMed Term Sheet. On October 20, 2025, we entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc., a Canadian biotechnology company developing regenerative treatments for organ fibrosis, topical scarring, and autoimmune diseases. The Term Sheet is non-binding and intended solely as a framework for continued discussions. There can be no assurance that a definitive agreement will be executed or that the proposed transactions will be completed on the terms contemplated or at all. |

Corporate Information

BioNexus Gene Lab Corp. was incorporated in Wyoming on May 12, 2017. Our principal corporate and MRNA Scientific Malaysia office is Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No. 5 Jalan Bangsar Utama 1, Kuala Lumpur, Malaysia. Our laboratory facilities are located in George Town, Penang, and at Lifecare Diagnostic Centre in Kuala Lumpur. Chemrex’s corporate office and distribution center is located at 4 Jalan CJ 1/6, Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia. Our telephone number is (+60) 18-221-8762 and our website is www.bionexusgenelab.com (information on or accessible through our website is not incorporated by reference into, and does not form part of, this prospectus).

| S-6 |

Emerging Growth Company and Smaller Reporting Company